Abstract:Rationale: Glioblastoma multiforme (GBM) almost invariably gain invasive phenotype with limited therapeutic strategy and ill-defined mechanism. By studying the aberrant expression landscape of gliomas, we find significant up-regulation of p-MAPK level in GBM and a potent independent prognostic marker for overall survival. DHHC family was generally expressed in glioma and closely related to the activation of MAPK signaling pathway, but its role and clinical significance in GBM development and malignant progression are yet to be determined. Method: Bioinformatics analysis, western blotting and immunohistochemistry (IHC) were performed to detect the expression of ZDHHC17 in GBM. The biological function of ZDHHC17 was demonstrated by a series of in vitro and in vivo experiments. Pharmacological treatment, flow cytometry, Transwell migration assay, Co- Immunoprecipitation and GST pulldown were carried out to demonstrate the potential mechanisms of ZDHHC17. Results: ZDHHC17 is up-regulated and coordinated with MAPK activation in GBM. Mechanistically, ZDHHC17 interacts with MAP2K4 and p38/JNK to build a signaling module for MAPK activation and malignant progression. Notably, the ZDHHC17-MAP2K4-JNK/p38 signaling module contributes to GBM development and malignant progression by promoting GBM cell tumorigenicity and glioma stem cell (GSC) self-renewal. Moreover, we identify a small molecule, genistein, as a specific inhibitor to disrupt ZDHHC17-MAP2K4 complex formation for GBM cell proliferation and GSC self-renewal. Moreover, genistein, identified herein as a lead candidate for ZDHHC17-MAP2K4 inhibition, demonstrated potential therapeutic effect in patients with ZDHHC17-expressing GBM. Conclusions: Our study identified disruption of a previously unrecognized signaling module as a target strategy for GBM treatment, and provided direct evidence of the efficacy of its inhibition in glioma using a specific inhibitor.

High β-catenin/Tcf-4 activity confers glioma progression via direct regulation of AKT2 gene expression.

Β- Catenin/tcf-4 Transcriptinal Regulate AKT2 Gene Promoting Malignant Transformation in Human Glioma

Alpha-Catenin Inhibits Glioma Cell Migration, Invasion, And Proliferation By Suppression Of Beta-Catenin Transactivation

Α-Catenin Inhibits Glioma Cell Migration, Invasion, and Proliferation by Suppression of Β-Catenin Transactivation.

AKT1 and AKT2 Promote Malignant Transformation in Human Brain Glioma LN229 Cells

AKT2 Expression is Associated with Glioma Malignant Progression and Required for Cell Survival and Invasion.

Notch1 Promotes Glioma Cell Migration and Invasion by Stimulating Β‐catenin and NF‐κB Signaling Via AKT Activation

GATA2 Promotes Glioma Progression Through EGFR/ERK/Elk-1 Pathway

Interruption of β-catenin suppresses the EGFR pathway by blocking multiple oncogenic targets in human glioma cells.

Beta-Catenin Induces Transcriptional Expression Of Pd-L1 To Promote Glioblastoma Immune Evasion

ATDC Contributes to Sustaining the Growth and Invasion of Glioma Cells Through Regulating Wnt/β-catenin Signaling.

TCAF2 Drives Glioma Cellular Migratory/invasion Properties Through STAT3 Signaling.

ZSCAN10 promotes cell proliferation, upregulates OCT4 expression, and activates Wnt/β-catenin signaling in glioma

Glucocorticoid Receptor Β Acts As a Co-activator of T-Cell Factor 4 and Enhances Glioma Cell Proliferation.

PAX3 Promotes Proliferation of Human Glioma Cells by WNT/β-Catenin Signaling Pathways

Up-regulation of LPCAT1 is correlated with poor prognosis and promotes tumor progression in glioblastoma

GSK-3 beta regulates tumor growth and angiogenesis in human glioma cells

Activation of JNK and P38 MAPK Mediated by ZDHHC17 Drives Glioblastoma Multiforme Development and Malignant Progression.

TBX15 facilitates malignant progression of glioma by transcriptional activation of TXDNC5

Β-Catenin Knockdown Inhibits the Proliferation of Human Glioma Cells in Vitro and in Vivo.

DTX2 Promotes Glioma Development Via Regulation of HLTF